awmsg logo



isavuconazole (Cresemba®)


Reference No. 2433

Publication date:
04/01/2017


Appraisal information

isavuconazole (Cresemba®) 100 mg capsule
isavuconazole (Cresemba®) 200 mg powder for concentrate for solution for infusion


Company: Basilea Pharmaceuticals Ltd
BNF category: Infections
NMG meeting date: 02/11/2016
AWMSG meeting date: 07/12/2016
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 3616
Ministerial ratification: 22/12/2016

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Isavuconazole (Cresemba®) is recommended as an option for use within NHS Wales for the treatment of invasive aspergillosis in adults and the treatment of mucormycosis in adult patients for whom amphotericin B is inappropriate. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download